MARKET

OMER

OMER

Omeros
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.64
-1.16
-7.84%
Closed 17:45 01/17 EST
OPEN
14.91
PREV CLOSE
14.80
HIGH
14.92
LOW
13.61
VOLUME
432.88K
TURNOVER
--
52 WEEK HIGH
20.92
52 WEEK LOW
12.52
MARKET CAP
735.13M
P/E (TTM)
-8.4969
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OMER and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

OMER News

  • Ocular Therapeutix: Executing On Dextenza's Launch, A Name To Own In 2020
  • Seeking Alpha - Article.12/30/2019 13:06
  • Hedge Funds Aren’t Crazy About Omeros Corporation (OMER) Anymore
  • Insider Monkey.12/20/2019 22:16
  • myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab
  • Business Wire.12/18/2019 13:30
  • Omeros Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors
  • Business Wire.12/16/2019 13:30

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About OMER

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.
More

Webull offers Omeros Corporation (OMER) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.